Resources
27 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 1/19/2022 (updated 3/26/2024)
With the worst opioid overdose death crisis in the United States history, urgent new approaches to assist people who use drugs onto medication for opioid use disorder are necessary. In this commentary, addiction medicine clinicians and drug user union representatives align to argue that conventional ways of buprenorphine initiation that require periods of withdrawal must be augmented with additional novel approaches to initiation.
Posted 3/22/2022 (updated 3/27/2024)
The purpose of this document is to provide detailed guidelines of the Nurse Care Manager Model of Office Based Addiction Treatment program for management of substance use disorders, with particular emphasis on treatment of opioid use disorder with buprenorphine (alone and in combination with naloxone) and naltrexone (oral and extended-release injectable formulations).
Posted 5/3/2022 (updated 3/27/2024)
Buprenorphine utilization is an effective treatment for opioid use disorder (OUD). Given the recent
increase in child maltreatment reports related to parental substance use, research should explore the correlation between buprenorphine treatment and child maltreatment–related outcomes.
Posted 7/25/2022 (updated 3/27/2024)
In 2019, the Addictions, Drug & Alcohol Institute (ADAI) at the University of Washington launched the “Meds First” program to provide onsite, low-barrier access to buprenorphine in partnership with six syringe services programs across WA State. A key component of the Meds First service model was the addition of care navigation to support client engagement and retention in OUD treatment.
Posted 9/7/2022 (updated 3/27/2024)
Buprenorphine (Suboxone) is an effective treatment for opioid use disorder (OUD). However, there have been widespread reports of diversion and misuse. This study examined motivations for nonprescribed buprenorphine use among rural residents.
Posted 3/21/2023 (updated 3/27/2024)
Researchers at Indiana University conducted one-on-one interviews with clinical providers and other stakeholders in the recovery arena to better understand the slow uptake of the drug most used to treat opioid use disorder. Biases against buprenorphine was the most consistent theme, though the reason for bias differed amongst stakeholders. Clinical providers and behavioral health care providers preferred the abstinence approach rather than use of medications.
Patients Treated With Buprenorphine in Emergency Departments More Likely To Continue After Discharge
Posted 4/11/2023 (updated 3/27/2024)
In this cohort study of 17,428 Medicaid-enrolled adults with an emergency department encounter for opioid use disorder, the buprenorphine treatment Opioid Hospital Quality Improvement Program (O-HQIP) pathway was associated with significantly increased prescription fills for buprenorphine within 30 days of discharge.
Posted 5/26/2023 (updated 3/27/2024)
Providers Clinical Support System (PCSS), a Substance Abuse and Mental Health Services Administration-funded grant initiative, announced the release of Practice-Based Guidelines: Buprenorphine in the Age of Fentanyl. The guide gives practitioners a blueprint on treating fentanyl use disorder based on available research combined with emerging clinical experience on the use of buprenorphine in the treatment of individuals using fentanyl and other highly potent synthetic opioids.
Posted 6/8/2023 (updated 3/27/2024)
Buprenorphine is a medication approved by the U.S. Food and Drug Administration to treat opioid use disorder (OUD) with a relatively low rate of triggering precipitated withdrawal in patients. Increased precipitated withdrawal rates have become a concern for practitioners in emergency departments when treating with buprenorphine with the prevalence of fentanyl in the drug supply.
Posted 3/7/2023 (updated 3/27/2024)
n December 2022, Congress eliminated the DATA-Waiver program registration allowing providers to prescribe buprenorphine to treat patients for OUD. The University of Vermont Center on Rural Addiction, a HRSA Rural Center of Excellence on Substance Use Disorders, offers an incentive to help defray previous training costs of $750 to each qualifying provider who obtained a DATA-Waiver. To qualify, providers must be practicing in a HRSA-designated rural county in Vermont, Maine, New Hampshire, or Northern New York.